# Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients

Source: https://onco.cc/trials/nct00103662/  
OnCo record `nct00103662` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Plerixafor in Multiple myeloma, run by Genzyme, a Sanofi Company, completed.

## Summary

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients is a phase 3 interventional study registered as NCT00103662 by Genzyme, a Sanofi Company, with 302 participants recorded, started 2005-01 and reaching its primary completion in 2006-10. Interventions recorded: Granulocyte colony-stimulating factor plus plerixafor, Granulocyte colony-stimulating factor plus placebo. Conditions recorded: Multiple Myeloma.

Linked to the drug Plerixafor because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00103662
- Phase: 3
- Setting: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 6*10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation
- Sponsor: Genzyme, a Sanofi Company
- Enrolled: 302

## Sources

- ClinicalTrials.gov NCT00103662: https://clinicaltrials.gov/study/NCT00103662

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Plerixafor](https://onco.cc/drugs/plerixafor/)
- companies: [Sanofi](https://onco.cc/companies/sanofi/)

---
JSON: https://onco.cc/api/v1/entities/nct00103662.json